VivoSeq
Neurology

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

14

Pipeline Programs↗

4

Active Trials↗

11

Companies Involved↗

Chronic Inflammatory Demyelinating Polyradiculoneuropathy is an emerging landscape with 14 programs across 11 companies. The most active players are GSK, UCB, EMD Serono. 1 therapy is approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

6/100

Mech. Concentration

29/100

Completion Rate

90/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

1 program

Phase 1UCB logo

UCB

1 program

Phase 2EMD Serono logo

EMD Serono

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

10programs
Small molecule550%
Monoclonal antibody550%

Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

14

clinical trials

Completed9 · 64%
Recruiting3 · 21%
Withdrawn1 · 7%
Not yet recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
Recruiting·Octapharma logoOctapharma·Phase 3·NCT04929236·30 enrolled
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Recruiting·Takeda logoTakeda·Phase 3·NCT06747351·59 enrolled
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Recruiting·Takeda logoTakeda·Phase 2·NCT06798012·36 enrolled
Safety and Efficacy of Obinutuzumab β in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Not yet recruiting·—·Preclinical·NCT07696377·24 enrolled
A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Completed·UCB logoUCB·Phase 2·NCT03861481·34 enrolled
Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
Completed·Novartis logoNovartis·Phase 3·NCT01625182·106 enrolled
Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Completed·Biogen logoBiogen·Phase 2·NCT00099489·67 enrolled
Effects of Single Plasma Exchange and Double Filtration Plasmapheresis (DFPP) on Peripheral Lymphocyte Phenotypes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Completed·—·Phase 1·NCT04742374·8 enrolled
A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Completed·BBaxalta now part of Shire·Phase 3·NCT02549170·138 enrolled
Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Completed·UUniversity of Aarhus·Phase 2·NCT01017159·30 enrolled
A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Completed·UCB logoUCB·Phase 2·NCT04051944·21 enrolled
Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Completed·IIstituto Clinico Humanitas·Phase 3·NCT06325943·37 enrolled
A Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of TAK-771 for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) in Japanese Subjects
Completed·Takeda logoTakeda·Phase 3·NCT05084053·26 enrolled
Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)
Withdrawn·JJohns Hopkins University·Phase 4·NCT01757574

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)